Clinical Trial Update: Neoadjuvant Atezolizumab in Localized Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant study of atezolizumab in localized bladder cancer has completed, with results posted on May 31, 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Transitional Cell Carcinoma of the Bladder

Drugs mentioned

• Tecentriq (atezolizumab)

Snippet

Sponsor: Lawrence Fong | Conditions: Carcinoma, Transitional Cell | Phase 2 | Status: COMPLETED | Results posted: 2024-05-31